Mylan Inc. has named John Thievon as president of Dey Pharma, its specialty pharmaceutical business.


Dey Pharma, John Thievon, president, Mylan, specialty pharmaceutical, MiddleBrook Pharmaceuticals, Heather Bresch








































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Thievon appointed president of Dey Pharma

December 12th, 2011

PITTSBURGH – Mylan Inc. has named John Thievon as president of Dey Pharma, its specialty pharmaceutical business.

Mylan said Monday that Thievon most recently was president and chief executive officer of MiddleBrook Pharmaceuticals, where he helped build the company from an 18-person startup to a 450-person organization before its assets were acquired by Victory Pharma.

"I am thrilled to be joining Mylan as Dey's new president," Thievon said in a statement. "I am excited about the potential of Dey's existing product portfolio and the introduction of new products. The momentum behind this business is a result of impressive execution by the strong team already in place at Dey, and I look forward to working alongside this team to maximize Dey's growth potential."

Thievon has more than 20 years of professional experience in strategic product launches, marketing, commercialization, sales penetration and distribution leadership, according to Mylan. Before leading MiddleBrook, he was executive vice president of commercial operations for Adams Respiratory Therapeutics over a nine-year span. He built Adams' marketing platform and led the launch of Mucinex, growing it to a $450 million brand before the company was sold to Reckitt Benckiser.

"I am extremely pleased to welcome John as our new leader of Mylan's specialty business. John's extensive experience growing a branded pharmaceutical business from the ground up and proven track record launching highly successful pharmaceutical brands, like Mucinex, is invaluable as we continue to build on our specialty business," commented Mylan president Heather Bresch. "Dey has been and continues to be a very valuable asset and important growth driver for Mylan, evidenced by the strong performance of this business. John's appointment demonstrates our continued commitment to invest in Dey and strengthen what we have in place in order to support the continued success of this business into the future."

Advertisement